Evaluation of therapeutical appropriateness in psychiatric treatment of schizophrenia, by integrating computer data records with clinical audit results

被引:0
作者
Farina, Giuseppina [1 ]
Menditto, Enrica [2 ]
Corea, Gabriella [1 ]
Manna, Sonia [1 ]
Pagliaro, Claudia [1 ]
Troncone, Chiara [1 ]
Linguiti, Claudio [1 ]
Orlando, Valentina [2 ]
Putignano, Daria [2 ]
Tari, Daniele Ugo [3 ]
Buffardi, Gianfranco [4 ]
机构
[1] ASL Caserta, Serv Controllo Interno Gest & Sistema Informat, Rome, Italy
[2] Univ Naples Federico II, CIRFF, Naples, Italy
[3] Univ Naples Federico II, Dipartimento Sci Biomed Avanzate, Naples, Italy
[4] ASL Caserta, UOSM Dist 13, Caserta, Italy
关键词
atypical antipsychotics; drug-utilization; schizophrenia; prescriptive pattern; clinical audit; ANTIPSYCHOTIC-DRUGS; BIPOLAR DISORDER; DOUBLE-BLIND; HALOPERIDOL; PERSISTENCE; RISPERIDONE; GUIDELINES; MANAGEMENT; OLANZAPINE; CLOZAPINE;
D O I
10.1708/2098.22684
中图分类号
R749 [精神病学];
学科分类号
100205 ;
摘要
Aim. The aim is to evaluate prescriptive patterns of atypical antipsychotic drugs for the treatment of schizophrenia in the LHU Caserta in 2011-2013, and to indicate potentially inappropriate therapy; to plan or schedule corrective/preventive activities to support the continuous improvement of health services. Methods. Retrospective cohort study, based on integration of health records and clinical audit. The study was performed in the following steps: data retrieval and analysis; comparison of data with international literature; editing of the Diagnostic-Therapeutic Path. The analysis was performed by using the administrative database of drug prescriptions and treatment plans in the SANIARP portal, a web platform available to specialist facilities and private and public pharmacies of LHU Caserta. The subject of our analysis was to gain information about the diagnosis and treatment of users of atypical antipsychotics in the LHU of Caserta in the years 2011-2013. Results. We identified 2,768 patients with at least one prescription of atypical antipsychotics and diagnosis coded in the study period. Schizophrenia is the most frequent diagnosis (31.1%) and the most common drug in use is olanzapine (29.1%). About 70% of schizophrenics were on monotherapy with no change in drug, 23.6% were under polytherapy and 7.9% made a switch. Discussion and conclusion. Our findings were a starting point for editing Diagnostic and Therapeutic Paths aimed at raising the awareness of the scientific community about the appropriateness of diagnosis and treatment in schizophrenia. Pharmacological treatment of schizophrenia should be focused on improving the overall quality of life aimed at remission and possible recovery, although difficult.
引用
收藏
页码:274 / 284
页数:11
相关论文
共 45 条
[1]  
[Anonymous], NAT GUID CLEAR PSYCH
[2]  
[Anonymous], NEI LUOGHI PERDUTI F
[3]  
[Anonymous], NOOS
[4]  
[Anonymous], GIORNALE ITALIANO PS
[5]  
[Anonymous], COCHRANE DATABASE SY
[6]  
[Anonymous], PHARM J
[7]  
[Anonymous], 2005, Canadian Journal of Psychiatry, V50, p1S
[8]  
[Anonymous], ATTUALITA NEL TRATTA
[9]   Rapid tranquilization for agitated patients in emergency psychiatric rooms: a randomized trial of olanzapine, ziprasidone, haloperidol plus promethazine, haloperidol plus midazolam and haloperidol alone [J].
Baldacara, Leonardo ;
Sanches, Marsal ;
Cordeiro, Daniel Cruz ;
Jackoswski, Andrea Parolin .
REVISTA BRASILEIRA DE PSIQUIATRIA, 2011, 33 (01) :30-39
[10]   Evidence-based guidelines for the pharmacological treatment of schizophrenia: recommendations from the British Association for Psychopharmacology [J].
Barnes, Thomas R. E. .
JOURNAL OF PSYCHOPHARMACOLOGY, 2011, 25 (05) :567-620